Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood maintains an Equal-Weight rating on DexCom (NASDAQ:DXCM) but lowers the price target from $120 to $75.

July 26, 2024 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley analyst Patrick Wood maintains an Equal-Weight rating on DexCom but significantly lowers the price target from $120 to $75.
The significant reduction in the price target from $120 to $75 by a major financial institution like Morgan Stanley is likely to negatively impact investor sentiment and could lead to a short-term decline in DexCom's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100